Klavinskis L S, Bergmeier L A, Gao L, Mitchell E, Ward R G, Layton G, Brookes R, Meyers N J, Lehner T
Department of Immunology, United Medical and Dental Schools of Guy's and St. Thomas' Hospital, London, United Kingdom.
J Immunol. 1996 Sep 15;157(6):2521-7.
The major routes of HIV transmission are through the rectal and cervico-vaginal mucosa. To prevent dissemination of HIV to the regional lymph nodes (LNs), an effective vaccine may need to stimulate CTL in the rectal or genital tract and the draining LNs. We report that mucosal immunization by the recto-oral and vagino-oral route or s.c. immunization targeting the iliac LNs with a particulate SIVp27:Ty-VLP vaccine elicits SIVgag-specific CTL in the regional LNs as well as in the spleen and PBMC. Targeted LN immunization with this vaccine elicited MHC class I-restricted CD8+ CTL responses, and the highest frequency of CTL was found in the iliac LNs. Moreover, SIVgag-specific CTL activity was detected in short term T cell lines established in mononuclear cells eluted from the rectal and cervico-vaginal mucosa. The relative frequency of CTL in short term cell lines prepared from the rectal mucosa (21/113 or 18.6%) was similar to that obtained from the cervico-vaginal mucosa (16/79 or 20.3%). Examination of the relative frequency of CTL to the T cell epitopes residing within SIVp27 showed a higher frequency in iliac LN cells to peptide aa 41-70 than in that to peptide aa 121-150, and this was significant after both recto-oral (chi-squared 6.500, p < 0.02) and vagino-oral (chi-squared = 10.391, p < 0.01) immunization. In contrast, the relative frequency of CTL in PBMC to peptide aa 41-70 (15.5%) was comparable to that elicited by peptide aa 121-150 (17.6%). This study provides novel evidence that mucosal or targeted LN immunization can generate anti-SIV CTL in the rectal and genital mucosa, in the draining LNs, and in the central lymphoid system.
HIV的主要传播途径是通过直肠和宫颈-阴道黏膜。为防止HIV扩散至局部淋巴结(LN),有效的疫苗可能需要在直肠或生殖道以及引流淋巴结中刺激CTL。我们报告,通过直肠-口腔和阴道-口腔途径进行黏膜免疫,或用颗粒状SIVp27:Ty-VLP疫苗靶向髂淋巴结进行皮下免疫,可在局部淋巴结以及脾脏和外周血单核细胞(PBMC)中引发SIVgag特异性CTL。用该疫苗进行靶向淋巴结免疫可引发MHC I类限制性CD8 + CTL反应,并且在髂淋巴结中发现CTL的频率最高。此外,在从直肠和宫颈-阴道黏膜洗脱的单核细胞中建立的短期T细胞系中检测到SIVgag特异性CTL活性。从直肠黏膜制备的短期细胞系中CTL的相对频率(21/113或18.6%)与从宫颈-阴道黏膜获得的频率(16/79或20.3%)相似。对SIVp27内T细胞表位的CTL相对频率检查显示,髂淋巴结细胞中针对肽段aa 41 - 70的CTL频率高于针对肽段aa 121 - 150的频率,在直肠-口腔免疫(卡方值6.500,p < 0.02)和阴道-口腔免疫(卡方值 = 10.391,p < 0.01)后均具有显著性。相比之下,PBMC中针对肽段aa 41 - 70的CTL相对频率(15.5%)与肽段aa 121 - 150引发的频率(17.6%)相当。本研究提供了新的证据,表明黏膜或靶向淋巴结免疫可在直肠和生殖黏膜、引流淋巴结以及中枢淋巴系统中产生抗SIV CTL。